
1. lancet oncol. 2015 may;16(5):e206-16. doi: 10.1016/s1470-2045(14)70481-4.

present status human papillomavirus vaccine development implementation.

herrero r(1), gonzález p(2), markowitz le(3).

author information: 
(1)prevention implementation group, section early detection and
prevention, international agency research cancer, lyon, france. electronic
address: herreror@iarc.fr.
(2)prevention implementation group, section early detection and
prevention, international agency research cancer, lyon, france; proyecto
epidemiológico guanacaste, liberia, guanacaste, costa rica.
(3)national center hiv/aids, viral hepatitis, std, tb prevention, centers
for disease control prevention, atlanta ga, usa.

oncogenic human papillomavirus (hpv) infection cause nearly all
cervical cancers proportion anogenital oropharyngeal cancers. 
a bivalent vaccine containing hpv 16 18 quadrivalent vaccine containing
hpv 6, 11, 16, 18 antigens use vaccination programmes around the
world. clinical trials, three vaccine doses provided 90-100% protection
against cervical infection pre-cancer related hpv 16 18 women aged 
15-26 years infected vaccination. partial cross-protection
against hpv types reported duration unknown. the
vaccines also efficacious prevention hpv 16 18 infections at
other anatomical sites sexes. immunobridging studies allowed licensing of
the vaccines use starting age 9 years sexes. two-dose schedules
elicit high antibody concentrations, leading recommendation two-dose
schedules girls aged 9-14 years. pre-licensure post-licensure studies
have provided data supporting vaccine safety. 2014, nonavalent vaccine
containing hpv 6, 11, 16, 18, 31, 33, 45, 52, 58 antigens licensed the
us food drug administration. hpv vaccination first introduced in
high-income countries owing vaccine cost, logistic challenges, competing
health priorities. since 2011, vaccine prices lowered, allowing the
introduction vaccine middle-income countries. funding the
vaccine gavi alliance 2012 led demonstration projects some
low-income countries. 2014, 57 countries included hpv
vaccine national health programmes. data several countries have
shown effect vaccination hpv infection associated disease, and
provided evidence herd immunity. expansion programmes countries the
highest burden disease beginning, efforts needed realise
the potential hpv vaccines.

copyright © 2015 elsevier ltd. rights reserved.

doi: 10.1016/s1470-2045(14)70481-4 
pmid: 25943065  [indexed medline]

